BRPI0922870A2 - uso de ao menos um composto da fórmula i, do compsoto ohod ou seus derivados farmaceuticamente aceitáveis, do composto na-ohod, composição farmacêutica e/ou nutracêutica e método cosmético - Google Patents

uso de ao menos um composto da fórmula i, do compsoto ohod ou seus derivados farmaceuticamente aceitáveis, do composto na-ohod, composição farmacêutica e/ou nutracêutica e método cosmético

Info

Publication number
BRPI0922870A2
BRPI0922870A2 BRPI0922870A BRPI0922870A BRPI0922870A2 BR PI0922870 A2 BRPI0922870 A2 BR PI0922870A2 BR PI0922870 A BRPI0922870 A BR PI0922870A BR PI0922870 A BRPI0922870 A BR PI0922870A BR PI0922870 A2 BRPI0922870 A2 BR PI0922870A2
Authority
BR
Brazil
Prior art keywords
compound
ohod
pharmaceutical
formula
pharmaceutically acceptable
Prior art date
Application number
BRPI0922870A
Other languages
English (en)
Inventor
Daniel López
Gerard Ávila Martín
Gwendolyn Barcelo Coblijn
Juana Barceló Estarellas
Julian Taylor Green
Pablo Vicente Ruiz Escribá
Rafael Álvarez Martínez
Silvia Teres Jiménez
Victoria Lladó Canellas
Xavier Busquets Xaubet
Original Assignee
Univ Illes Balears
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42242375&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0922870(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Illes Balears filed Critical Univ Illes Balears
Publication of BRPI0922870A2 publication Critical patent/BRPI0922870A2/pt
Publication of BRPI0922870A8 publication Critical patent/BRPI0922870A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • AIDS & HIV (AREA)
BRPI0922870A 2008-12-09 2009-12-04 uso de ao menos um composto da fórmula i, do composto ohod ou seus derivados farmaceuticamente aceitáveis, do composto na-ohod, composição farmacêutica e/ou nutracêutica e método cosmético BRPI0922870A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200803480A ES2342997B1 (es) 2008-12-09 2008-12-09 Alpha derivados de acidos grasos cis-monoinsaturados para ser usados como medicamento.
PCT/ES2009/070561 WO2010066931A1 (es) 2008-12-09 2009-12-04 Alfa-derivados de ácidos grasos cis-monoinsaturados para ser usados como medicamento

Publications (2)

Publication Number Publication Date
BRPI0922870A2 true BRPI0922870A2 (pt) 2016-01-12
BRPI0922870A8 BRPI0922870A8 (pt) 2017-12-26

Family

ID=42242375

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0922870A BRPI0922870A8 (pt) 2008-12-09 2009-12-04 uso de ao menos um composto da fórmula i, do composto ohod ou seus derivados farmaceuticamente aceitáveis, do composto na-ohod, composição farmacêutica e/ou nutracêutica e método cosmético

Country Status (18)

Country Link
US (3) US9000042B2 (pt)
EP (4) EP2842556B1 (pt)
JP (2) JP5711140B2 (pt)
KR (1) KR101683643B1 (pt)
CN (1) CN102355897B (pt)
AU (6) AU2009326993B2 (pt)
BR (1) BRPI0922870A8 (pt)
CA (1) CA2745052C (pt)
DK (3) DK2374453T3 (pt)
ES (5) ES2342997B1 (pt)
HU (2) HUE056170T2 (pt)
IL (1) IL213354A (pt)
MX (1) MX2011005978A (pt)
PL (3) PL3366285T3 (pt)
PT (4) PT2842555T (pt)
RU (1) RU2531353C2 (pt)
SI (1) SI3366285T1 (pt)
WO (1) WO2010066931A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2342997B1 (es) 2008-12-09 2011-06-06 Universitat De Les Illes Balears Alpha derivados de acidos grasos cis-monoinsaturados para ser usados como medicamento.
WO2011089265A1 (en) * 2010-01-25 2011-07-28 Bridge Bioresearch Plc Use of fatty acid compounds for lowering blood glucose levels
ES2401629B1 (es) * 2011-10-07 2014-03-04 Universitat De Les Illes Balears Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos.
WO2013132092A1 (en) 2012-03-09 2013-09-12 Pensieve International Plc Use of monounsaturated fatty acid compounds for controlling the body weight of a dog or a cat
AU2015334964B2 (en) * 2014-10-21 2019-06-20 Universitat De Les Illes Balears Method for the synthesis of hydroxy-triglycerides and uses thereof for the prevention and treatment of diseases
WO2019099664A1 (en) * 2017-11-16 2019-05-23 The Research Foundation For The State University Of New York Use of 2-hydroxyoleic acid for the treatment of systemic lupus erythematosus and other immune pathologies
CA3233141A1 (en) * 2020-01-29 2021-08-05 Universitat De Les Illes Balears Alpha-hydroxylated fatty acids metabolites, medical uses of same and use as biomarkers
ES2911474B2 (es) * 2020-11-17 2023-02-06 Univ Illes Balears Profarmacos de acidos grasos monoinsaturados y sus metabolitos: usos medicos y como biomarcadores
US20230181515A1 (en) * 2021-12-09 2023-06-15 The Florida International University Board Of Trustees Treatment and prevention of infections using vegetable oil-derived polyols

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4928172B1 (pt) * 1969-10-27 1974-07-24
CH558321A (de) * 1971-08-03 1975-01-31 Ciba Geigy Ag Verfahren zur herstellung von carbonsaeuren bezw. carbonsaeuresalzen.
US3931306A (en) * 1973-10-23 1976-01-06 International Flavors & Fragrances Inc. Process for producing isomer mixtures containing high proportions of cis-2-methyl-3-pentenoic acid
DE2448339A1 (de) * 1974-10-10 1976-04-22 Basf Ag Verfahren zur herstellung von olefinisch ungesaettigten carbonsaeureestern
DE2559201B2 (de) * 1975-12-30 1978-06-15 Hoechst Ag, 6000 Frankfurt Organozinnverbindungen und ihre Verwendung als Stabilisatoren
US4241097A (en) * 1979-09-13 1980-12-23 International Flavors & Fragrances Inc. Use of benzodionones in augmenting or enhancing the aroma and taste of a foodstuff
US4391757A (en) * 1981-11-27 1983-07-05 Carstab Corporation Organic antimony containing stabilizer compositions for halogenated polymers
JPS5899432A (ja) * 1981-12-09 1983-06-13 Maruzen Sekiyu Kagaku Kk 不飽和脂肪酸またはその塩およびそれからなる抗菌剤
US4551279A (en) * 1984-01-09 1985-11-05 G. D. Searle & Co. Protease inhibitors
FR2609032B1 (fr) * 1986-12-30 1990-01-05 Centre Nat Rech Scient Epoxydes fonctionnels enantiomeriquement purs, leur procede de preparation et leur application comme synthons chiraux
US4808403A (en) * 1987-03-17 1989-02-28 International Flavors & Fragrances Inc. Use of N,N-diethyl-m-toluamide and/or the ethyl ester of 2-methyl-3-pentenoic acid as insect attractants
US5504107A (en) * 1990-01-12 1996-04-02 The Ohio State University Research Foundation Optically pure 4-alkenyl- or 4-alkanyl-2-hydroxytetronic acids and pharmaceutical use thereof
GB9003201D0 (en) * 1990-02-13 1990-04-11 Unilever Plc Cosmetic composition
US5208260A (en) * 1990-03-29 1993-05-04 G. D. Searle & Co. Vinyl Glycine derivatives for memory and learning enhancement or treatment of a cognitive disorder
US5198250A (en) 1990-07-16 1993-03-30 Lipotech Partners Limited Partnership Food and pharmaceutical compositions containing short chain monounsaturated fatty acids and methods of using
DE69228622T2 (de) * 1991-04-10 1999-12-02 Eugene J. Van Scott Verwendung von 2-Hydroxycarbonsäure oder deren Derivaten enthaltende Zusammensetzung zur Linderung von Wechseln Nagelveränderungen
US6300373B1 (en) 1993-09-10 2001-10-09 American Biogenetic Sciences, Inc. Antiproliferative and neurotrophic molecules
JP3489703B2 (ja) * 1995-10-23 2004-01-26 株式会社ノエビア 微細エマルション組成物
US5856537A (en) * 1996-06-26 1999-01-05 The Scripps Research Institute Inhibitors of oleamide hydrolase
JPH10182338A (ja) * 1996-12-20 1998-07-07 Noevir Co Ltd 水中油型乳化組成物
JP2001523695A (ja) * 1997-11-24 2001-11-27 ザ スクリップス リサーチ インスティテュート ギャップ結合連絡の阻害剤
GB9926833D0 (en) * 1999-11-15 2000-01-12 Univ Sunderland Compositions
GB2365427B (en) * 2000-08-07 2003-04-02 Sofitech Nv Surfactant
ES2186576B1 (es) 2001-10-11 2004-09-16 Universitat De Les Illes Balears Acido 2-hidroxioleico para utilizar como medicamento.
US6702756B2 (en) * 2001-12-11 2004-03-09 University Technologies International Inc. Method and apparatus for diagnosing neurological impairment
WO2003062244A1 (en) * 2002-01-22 2003-07-31 Syngenta Participations Ag Phenyl substituted heterocyclic compounds useful as herbicides
US7462349B2 (en) * 2002-10-24 2008-12-09 Nurit Kalderon Beta interferon for the treatment of chronic spinal cord injury
US20040214215A1 (en) * 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
ES2572454T3 (es) * 2003-05-15 2016-05-31 Ampio Pharmaceuticals Inc Tratamiento de enfermedades mediadas por los linfocitos T
ES2229935B1 (es) * 2003-10-10 2006-10-01 Universitat De Les Illes Balears Utilizacion del acido hidroxioleico y compuestos analagos del mismo como aditivos alimentarios funcionales.
KR100756890B1 (ko) * 2005-08-19 2007-09-07 경희대학교 산학협력단 신경세포 보호활성을 갖는 올레산을 함유하는 조성물
JP2009051732A (ja) * 2005-12-13 2009-03-12 Meiji Seika Kaisha Ltd Ｐｐａｒリガンド活性を有する組成物
EP2265654A1 (en) * 2008-04-18 2010-12-29 Commonwealth Scientific and Industrial Research Organisation Polyurethanes
WO2009127009A1 (en) 2008-04-18 2009-10-22 Commonwealth Scientific And Industrial Research Organisation Condensation polymers
ES2342997B1 (es) 2008-12-09 2011-06-06 Universitat De Les Illes Balears Alpha derivados de acidos grasos cis-monoinsaturados para ser usados como medicamento.

Also Published As

Publication number Publication date
IL213354A (en) 2017-06-29
HUE056170T2 (hu) 2022-01-28
DK3366285T3 (da) 2021-10-04
AU2016228171A1 (en) 2016-09-29
AU2016228167A1 (en) 2016-09-29
EP3366285B1 (en) 2021-06-30
EP2842556A3 (en) 2015-08-05
PT2374453E (pt) 2015-04-28
PT2842556T (pt) 2018-03-19
EP3366285A1 (en) 2018-08-29
CN102355897B (zh) 2014-06-04
ES2535498T8 (es) 2016-08-19
ES2342997A1 (es) 2010-07-20
PT3366285T (pt) 2021-10-07
AU2009326993A1 (en) 2011-07-07
DK2374453T3 (en) 2015-03-30
AU2019222955B2 (en) 2020-11-05
US20110294883A1 (en) 2011-12-01
PL2842556T3 (pl) 2018-07-31
WO2010066931A1 (es) 2010-06-17
EP2842555B1 (en) 2018-04-18
CA2745052A1 (en) 2010-06-17
ES2535498T3 (es) 2015-05-12
EP2374453A1 (en) 2011-10-12
IL213354A0 (en) 2011-07-31
RU2011128335A (ru) 2013-01-20
AU2019222955A1 (en) 2019-09-19
HUE037396T2 (hu) 2018-08-28
AU2018229472B2 (en) 2019-07-18
KR20110126100A (ko) 2011-11-22
MX2011005978A (es) 2011-10-11
EP2842556B1 (en) 2018-01-31
US9000042B2 (en) 2015-04-07
EP2842556A2 (en) 2015-03-04
RU2531353C2 (ru) 2014-10-20
JP2015061856A (ja) 2015-04-02
PL2374453T3 (pl) 2015-07-31
WO2010066931A4 (es) 2010-08-05
KR101683643B1 (ko) 2016-12-07
ES2342997B1 (es) 2011-06-06
AU2018229474B2 (en) 2019-08-22
US20150297548A1 (en) 2015-10-22
ES2673406T3 (es) 2018-06-21
EP2374453B1 (en) 2015-02-18
JP2012511510A (ja) 2012-05-24
CN102355897A (zh) 2012-02-15
SI3366285T1 (sl) 2021-11-30
US9730906B2 (en) 2017-08-15
EP2842555A3 (en) 2015-04-15
AU2009326993B2 (en) 2016-06-16
PL3366285T3 (pl) 2022-01-10
DK2842556T3 (en) 2018-03-26
JP5711140B2 (ja) 2015-04-30
AU2018229472A1 (en) 2018-10-04
ES2661412T3 (es) 2018-03-28
EP2374453A4 (en) 2012-05-30
ES2899274T3 (es) 2022-03-10
BRPI0922870A8 (pt) 2017-12-26
EP2842555A2 (en) 2015-03-04
AU2018229474A1 (en) 2018-10-04
PT2842555T (pt) 2018-07-06
US10588883B2 (en) 2020-03-17
CA2745052C (en) 2017-11-07
US20180193297A1 (en) 2018-07-12

Similar Documents

Publication Publication Date Title
BRPI0922870A2 (pt) uso de ao menos um composto da fórmula i, do compsoto ohod ou seus derivados farmaceuticamente aceitáveis, do composto na-ohod, composição farmacêutica e/ou nutracêutica e método cosmético
CY2024007I1 (el) Γλυκοπυρανοζυλο-υποκατεστημενα παραγωγα βενζονιτριλιου, φαρμακευτικες συνθεσεις που περιεχουν τετοιες ενωσεις, η χρηση τους και μεθοδοι παρασκευης τους
BRPI0716633A2 (pt) compostos derivados de piridin-3-ila, composiÇço farmacÊutica e uso de um composto como agente imunomodulador
BRPI0809667A2 (pt) Composto, medicamento e composição farmacêutica que o contém e uso do composto
BRPI0821115A2 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
BRPI0916235A2 (pt) composto, composição farmacêutica, uso do composto ou da composição, e, método para tratar um paciente infectado com hcv
BRPI0720124A2 (pt) Composições farmacêuticas e seus métodos de uso.
BR112012003842A2 (pt) composição farmacêutica, método de formulação e uso da mesma
BRPI0915897A2 (pt) compostos derivados triazóis, composições farmacêuticas e combinações dos mesmos e seus usos
BRPI0910557A2 (pt) composições farmacêuticas de paclitaxel, análogos de paclitaxel ou conjugados de paclitaxel e métodos relacionados de preparação e uso.
BRPI0806531A2 (pt) Composto, composição farmacêutica, agente terapêutico, e, uso do composto.
CR10229A (es) Derivados de 1,2,4,5,-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
BRPI0607198A2 (pt) composição, uso da composição método de tratamento doenças, e, embalagem farmacêutica
BRPI0917001A2 (pt) composto, composição farmacêutica, e, uso de um composto ou uma composição farmacêutica
BRPI0921699A2 (pt) complexo antioxidante, composicoes cosmeticas e farmaceutica contendo o referido complexo e uso deste complexo
PL2364983T3 (pl) Nowa pochodna tricykliczna lub jej farmaceutycznie dopuszczalne sole, sposób jej wytwarzania, oraz zawierająca ją kompozycja farmaceutyczna
BRPI0915120A2 (pt) composto derivado de oxima, uso do referido composto e composição farmacêutica
BRPI1014865A2 (pt) "composição e formulação farmacêutica comreendendo derivados de nitrocatecol, e, método para fabricar uma composição ou formulação farmacêutica"
BRPI1009392A2 (pt) "formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica."
IL200153A (en) History of Ethnon, including and use of pharmaceutical preparations
BRPI0916571A2 (pt) composto derivado de alquilaminometiloxazolidinona tricíclo, medicamento e composição farmacêutica que o contém e uso do composto
BRPI0909296A2 (pt) uso de pelo menos um princípio ativo, e, composições cosmética, farmacêutica e/ou dermatológica
BRPI0915552A2 (pt) derivados de ciclosporina, seu uso e sua composição farmacêutica
CR10665A (es) Nuevos derivados de diosmetina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
BRPI0717369A2 (pt) Composto, medicamento, composição farmacêutica que o contém e uso do composto.

Legal Events

Date Code Title Description
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/201 (2006.01), A23L 33/12 (2016.01), A61K

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]